Default company panoramic image

Regenerative Medical Solutions

RMS utilizes patented technology to grow iPSC-derived pancreatic cells for dual use as research tools and direct cell therapeutic targeting diabetes

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Madison, WI, USA
  • Currency USD
  • Founded January 2012
  • Employees 10
  • Incorporation Type C-corp
  • Website

Company Summary

Regenerative Medical Solutions was established to commercialize patented technology, exclusively licensed from the University of Wisconsin, to grow iPSC-derived pancreatic cells for dual use as research tools and direct cell therapeutic targeting diabetes. RMS is utilizing and building upon patented technology under world renowned stem cell scientist and pancreatic transplant surgeon, Dr. Jon Odorico, and RMS’ dedicated team of scientists.


  • Default avatar
    Anthony D Kolton

    Mr. Kolton has had extensive experience and a successful track record in both start-up and technology companies. He founded LIM in 1988 with $4,000 in capital and, under his direction as President, turned the company into a business with revenues over $20 million per year. In December 2009, LIM was sold to Morningstar for over $50 million. Mr. Kolton earned a BS in Accounting along with his CPA certificate. He has MA in Taxation and a JD.

  • Default avatar
    Jon Odorico, M.D., F.A.C.S
    Chief Scientific Officer

    Dr. Jon Odorico currently serves as the Chief Scientific Officer of RMS and is responsible for the overall scientific direction of the company. Dr. Odorico is also an Associate Professor, Department of Surgery, Division of Organ Transplantation at the University of Wisconsin-Madison in Madison, WI. Dr. Odorico is certified by the American Board of Surgery and specializes in pancreas transplants, islet cell transplants and multi-organ transplants.

  • Default avatar
    Xiaofang Xu, PhD
    Lead Scientist, Diabetes Team

    Dr. Xu is in charge of the scientific direction of the diabetes team at RMS. Dr. Xu has conducted extensive research in the creation of the ProgenMix™ media formulation. She also has extensive research experience in differentiation of pancreatic lineage cells from human embryonic stem cells and induced pluripotent stem cells. She received her Bachelor of Medicine from Shanghai Medical University and a PhD from the University of Wisconsin-Madison.

  • Default avatar
    Tom Joyce
    Vice President

    Tom Joyce is VP of Corporate Development and Administration of RMS. In this role he manages day-to-day operations of finance, marketing and logistics for RMS. He previously was a key market researcher with Logical Information Machines specializing in developing data, conducting research and streamlining financial operations. Mr. Joyce graduated Summa Cum Laude with a degree in Finance and Banking from the University of Missouri-Columbia.